Clinical significance of 2-[ 18F]fluoro-2-deoxy-D-glucose positron emission tomography for the assessment of 131I-metaiodobenzylguanidine therapy in malignant phaeochromocytoma

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 38, Issue 10, 2011, Pages 1869-1875

  Nakazawa, Azusa ^a   Higuchi, Tetsuya ^a   Oriuchi, Noboru ^a   Arisaka, Yukiko ^a   Endo, Keigo ^a  

^a GUNMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

2 18F fluoro 2 deoxy D glucose (FDG) positron emission tomography (PET); 131I metaiodobenzylguanidine (MIBG); Malignant phaeochromocytoma; Phaeochromocytoma; Radionuclide therapy

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; CATECHOLAMINE; FLUORODEOXYGLUCOSE F 18;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; NUCLEAR MAGNETIC RESONANCE IMAGING; PHEOCHROMOCYTOMA; POSITRON EMISSION TOMOGRAPHY; TREATMENT RESPONSE;

3-IODOBENZYLGUANIDINE; ADULT; AGED; CATECHOLAMINES; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PHEOCHROMOCYTOMA; POSITRON-EMISSION TOMOGRAPHY; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 80455174003     PISSN: 16197070     EISSN: 16197089     Source Type: Journal    
DOI: 10.1007/s00259-011-1872-3     Document Type: Article

References (16)

1. Ilias I, Pacak K. A clinical overview of pheochromocytomas/paragangliomas and carcinoid tumors. Nucl Med Biol 2008;35:S27-34.
2. Lenders JW. Biochemical diagnosis of pheochromocytoma and paraganglioma. Ann Endocrinol (Paris) 2009;70:161-5.
3. Guller U, Turek J, Eubanks S, Delong ER, Oertli D, Feldman JM. Detecting pheochromocytoma: defining the most sensitive test. Ann Surg 2006;243:102-7. (Pubitemid 43054061)
4. Salmenkivi K, Heikkilä P, Haglund C, Arola J. Malignancy in pheochromocytomas. APMIS 2004;112:551-9. (Pubitemid 40040182)
5. Havekes B, Lai EW, Corssmit EP, Romijn JA, Timmers HJ, Pacak K. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging. Q J Nucl Med Mol Imaging 2008;52:419-29.
6. John H, Ziegler WH, Hauri D, Jaeger P. Pheochromocytomas: can malignant potential be predicted? Urology 1999;53:679-83. (Pubitemid 29163029)
7. Eisenhofer G, Bornstein SR, Brouwers FM, Cheung NK, Dahia PL, de Krijger RR, et al. Malignant pheochromocytoma: current status and initiatives for future progress. Endocr Relat Cancer 2004;11:423-36. (Pubitemid 39331275)
8. Hoefnagel CA, Schornagel J, Valdés Olmos RA. [131I] metaiodobenzylguanidine therapy of malignant pheochromocytoma: interference of medication. J Nucl Biol Med 1991;35:308-12.
9. Sisson J, Shapiro B, Beierwaltes WH, Nakajo M, Glowniak J, Mangner T, et al. Treatment of malignant pheochromocytoma with a new radiopharmaceutical. Trans Assoc Am Physicians 1983;96:209-17.
10. Ackery DM, Troncone L. Session on the role of [131I] metaiodobenzylguanidine in the treatment of malignant phaeochromocytoma. Chairmen's report. J Nucl Biol Med 1991;35:318-20.
11. Safford SD, Coleman RE, Gockerman JP, Moore J, Feldman JM, Leight Jr GS, et al. Iodine-131 metaiodobenzylguanidine is an effective treatment for malignant pheochromocytoma and paraganglioma. Surgery 2003;134:956-62.
12. Gonias S, Goldsby R, Matthay KK, Hawkins R, Price D, Huberty J, et al. Phase II study of high-dose [131I]metaiodobenzylguanidine therapy for patients with metastatic pheochromocytoma and paraganglioma. J Clin Oncol 2009;27:4162-8.
13. Menzel C, Graichen S, Berner U, Risse JH, Diehl M, Döbert N, et al. Monitoring the efficacy of iodine-131-MIBG therapy using fluorine-18-FDG-PET. Acta Med Austriaca 2003;30:37-40. (Pubitemid 36649254)
14. Nwosu AC, Jones L, Vora J, Poston GJ, Vinjamuri S, Pritchard DM. Assessment of the efficacy and toxicity of (131) I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 2008;98:1053-8. (Pubitemid 351399810)
15. Wahl RL, Jacene H, Kasamon Y, Lodge MA. From RECIST to PERCIST: evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009;50:122S-50.
16. Taggart DR, Han MM, Quach A, Groshen S, Ye W, Villablanca JG, et al. Comparison of iodine-123 metaiodobenzylguanidine (MIBG) scan and [18F]fluorodeoxyglucose positron emission tomography to evaluate response after iodine-131 MIBG therapy for relapsed neuroblastoma. J Clin Oncol 2009;27:5343-9.